clinical trial · NCT05515536
A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia
Friedreich AtaxiaVatiquinone
brief summary
The primary objective of this study is to assess the long-term safety of vatiquinone in participants with Friedreich ataxia (FA) previously exposed to vatiquinone.
started
Dec 8, 2022
primary completion
Dec 31, 2027
completion
Dec 31, 2027
last updated
Oct 30, 2025
detailed description
This long-term, open-label study will serve as a continued access study for participants with FA who have previously participated in a vatiquinone study. The purpose of this study is to assess continued safety and efficacy of vatiquinone dosing in previously treated participants. This study addresses the medical need for participants to continue vatiquinone with a planned study duration of 3 years.
official title
Long-Term Open-Label Study to Assess the Safety and Efficacy of Vatiquinone in Patients With Friedreich Ataxia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol